Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Sirisha Narayanabhatia, M.Sc., Aktar Alam, BCA, Kunal Ghosh Roy, M.Sc., Ashish Choudhary, M.Sc., Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2018-99-114610

Published: 2018

Journal Articles

Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study

Tomas Stopka, MD PhD, Jarmila Vargova, MSc, Karina Vargova, PhD, Nina Dusilkova, MD, Vojtech Kulvait, MSc, Vit Pospisil, PhD, Jiri Zavadil, PhD, Marek Trneny, Pavel Klener, MD PhD

Blood (2016) 128 (22): 1767.

https://doi.org/10.1182/blood.V128.22.1767.1767

Published: 2016

Journal Articles

Graded PU.1 Levels Regulate Granulocyte Vs. Macrophage Genes Via Multiple Enhancer Elements

Vitek Pospisil, PhD, Pavle Krsmanovic, PhD, Jan Valecka, MSc, Kamila Chramostová, Vojtech Kulvait, MSc, Jiri Zavadil, PhD, Martin Vokurka, MD PhD, Peter Laslo, PhD, Tomas Stopka, MD PhD

Blood (2016) 128 (22): 403.

https://doi.org/10.1182/blood.V128.22.403.403

Published: 2016

Journal Articles

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Kamila Polgarova, MD, Vojtech Kulvait, MSc, Karina Vargova, PhD, Lubomir Minarik, MD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Tomas Stopka, MD PhD

Blood (2016) 128 (22): 4294.

https://doi.org/10.1182/blood.V128.22.4294.4294

Published: 2016

Journal Articles

Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness

Tomas Stopka, MD PhD, Karina Vargova, MSc, PhD, Vojtech Kulvait, MSc, Jarmila Vargova, MSc, Nina Dusilkova, MD, Anna Jonasova, MD PhD

Blood (2015) 126 (23): 4103.

https://doi.org/10.1182/blood.V126.23.4103.4103

Published: 2015

Journal Articles

Somatic Mutation-Detecting Algorithm Enables Analysis of MDS Patients during Azacitidine Therapy

Tomas Stopka, MD PhD, Karin Vargova, PhD, Vojtech Kulvait, MSc., Nina Dusilkova, MD, Anna T. Jonasova, MD

Blood (2014) 124 (21): 5600.

https://doi.org/10.1182/blood.V124.21.5600.5600

Published: 2014

Journal Articles

Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia

Katerina Machova Polakova, Vojtech Kulvait, Jana Linhartova, Adela Brouckova, Simona Soverini, Monika Jaruskova, Caterina de Benedittis, Torsten Haferlach, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Alexander Kohlmann, PhD, Hana Klamova

Blood (2013) 122 (21): 3987.

https://doi.org/10.1182/blood.V122.21.3987.3987

Published: 2013

Journal Articles

Analysis of Mantle Cell Lymphoma Patients Reveals Novel Regulatory Circuits Involving MicroRNAs and Their Targets

Vojtech Kulvait, Vit Pospisil, Karin Vargova, Marek Trneny, Pavel Klener, Jr., Tomas Stopka, MD, PhD

Blood (2011) 118 (21): 4624.

https://doi.org/10.1182/blood.V118.21.4624.4624

Published: 2011

Journal Articles

Pattern of Mir-155 and PU.1 Expression in CLL/SLL and Aggressive Lymphomas

Tomas Stopka, MD, PhD, Karin Vargova, Hana Huskova, Pavel Burda, PhD, Nikola Curik, Petra Vlckova, Vojtech Kulvait, Vit Pospisil, Filipp Savvulidi, Emanuel Necas, Marek Mraz, MD, Sarka Pospisilova, Dr, PhD, Jiri Mayer, MD, PhD, Josef Karban, Petra Obrtlikova, MD, PhD, Marek Trneny

Blood (2011) 118 (21): 4600.

https://doi.org/10.1182/blood.V118.21.4600.4600

Published: 2011

Journal Articles

MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia

Karin Vargova, Nikola Curik, Pavel Burda, Petra Basova, Vojtech Kulvait, Vit Pospisil, Filipp Savvulidi, Juraj Kokavec, Emanuel Necas, Adela Berkova, Petra Obrtlikova, Josef Karban, Marek Mraz, Sarka Pospisilova, Jiri Mayer, Marek Trneny, Jiri Zavadil, Tomas Stopka

Blood (2011) 117 (14): 3816–3825.

https://doi.org/10.1182/blood-2010-05-285064

Published: 2011

Includes: Supplemental data

Journal Articles

Active Chromatin Structure near MYB Occupancy at the Mir-155 Host Gene Promoter Coincides with Increased Mir-155 and MYB Levels In Chronic Lymphocytic Leukemia

Tomas Stopka, MD, PhD, Karin Vargova, Nikola Curik, Pavel Burda, Petra Basova, Vit Pospisil, Vojtech Kulvait, Filipp Savvulidi, Emanuel Necas, MD, PhD, Adela Berkova, MD, Petra Obrtlikova, MD, Josef Karban, MD, Marek Trneny, MD, PhD, Jiri Zavadil, PhD

Blood (2010) 116 (21): 3589.

https://doi.org/10.1182/blood.V116.21.3589.3589

Published: 2010

NARROW

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study

Graded PU.1 Levels Regulate Granulocyte Vs. Macrophage Genes Via Multiple Enhancer Elements

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness

Somatic Mutation-Detecting Algorithm Enables Analysis of MDS Patients during Azacitidine Therapy

Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia

Analysis of Mantle Cell Lymphoma Patients Reveals Novel Regulatory Circuits Involving MicroRNAs and Their Targets

Pattern of Mir-155 and PU.1 Expression in CLL/SLL and Aggressive Lymphomas

MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia

Active Chromatin Structure near MYB Occupancy at the Mir-155 Host Gene Promoter Coincides with Increased Mir-155 and MYB Levels In Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only